DE60116146T2 - Konjugate definierter stöchiometrie - Google Patents

Konjugate definierter stöchiometrie Download PDF

Info

Publication number
DE60116146T2
DE60116146T2 DE60116146T DE60116146T DE60116146T2 DE 60116146 T2 DE60116146 T2 DE 60116146T2 DE 60116146 T DE60116146 T DE 60116146T DE 60116146 T DE60116146 T DE 60116146T DE 60116146 T2 DE60116146 T2 DE 60116146T2
Authority
DE
Germany
Prior art keywords
linker
biomolecule
conjugate
molecular weight
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60116146T
Other languages
German (de)
English (en)
Other versions
DE60116146D1 (de
Inventor
Eva Hoess
Herbert Andres
Frederic Donie
Rudolf Vogel
Hans-Peter Josel
Rupert Herrmann
Herbert Von Der Eltz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10048417A external-priority patent/DE10048417A1/de
Priority claimed from EP01107491A external-priority patent/EP1245956A1/en
Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH
Application granted granted Critical
Publication of DE60116146D1 publication Critical patent/DE60116146D1/de
Publication of DE60116146T2 publication Critical patent/DE60116146T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/961—Chemistry: molecular biology and microbiology including a step of forming, releasing, or exposing the antigen or forming the hapten-immunogenic carrier complex or the antigen per se
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Catalysts (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
DE60116146T 2000-09-29 2001-09-26 Konjugate definierter stöchiometrie Expired - Lifetime DE60116146T2 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE10048417 2000-09-29
DE10048417A DE10048417A1 (de) 2000-09-29 2000-09-29 Verbindungen mit verzweigtem Linker
EP01107491 2001-03-29
EP01107491A EP1245956A1 (en) 2001-03-29 2001-03-29 Conjugates of defined stoichiometry
DE60116146 2001-09-26
PCT/EP2001/011101 WO2002027317A2 (en) 2000-09-29 2001-09-26 Conjugates of defined stoichiometry

Publications (2)

Publication Number Publication Date
DE60116146D1 DE60116146D1 (de) 2006-01-26
DE60116146T2 true DE60116146T2 (de) 2006-09-14

Family

ID=26007222

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60116146T Expired - Lifetime DE60116146T2 (de) 2000-09-29 2001-09-26 Konjugate definierter stöchiometrie

Country Status (9)

Country Link
US (1) US7897404B2 (cg-RX-API-DMAC10.html)
EP (2) EP1364208B1 (cg-RX-API-DMAC10.html)
JP (1) JP3836429B2 (cg-RX-API-DMAC10.html)
AT (1) ATE313796T1 (cg-RX-API-DMAC10.html)
AU (1) AU2001289923A1 (cg-RX-API-DMAC10.html)
CA (1) CA2420768C (cg-RX-API-DMAC10.html)
DE (1) DE60116146T2 (cg-RX-API-DMAC10.html)
ES (1) ES2254489T3 (cg-RX-API-DMAC10.html)
WO (1) WO2002027317A2 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
CA2414076A1 (en) 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
WO2012055815A1 (en) 2010-10-25 2012-05-03 Roche Diagnostics Gmbh Use of signal enhancing compounds in electrochemiluminescence detection
US10131682B2 (en) 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
AU2018342105B2 (en) 2017-09-26 2023-11-16 University Of Florida Research Foundation, Incorporated Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders
US20220331442A1 (en) * 2018-03-15 2022-10-20 Levim Biotech Llp Antibody-biomolecule conjugates linked through multifunctional macromolecule and uses thereof
AU2020348916B2 (en) * 2019-09-20 2025-12-18 University Of Florida Research Foundation, Incorporated Detection of antibodies against RAN proteins from serum and tissue lysates
WO2021072187A2 (en) 2019-10-10 2021-04-15 University Of Florida Research Foundation, Incorporated Ran proteins as biomarkers in cag/ctg expansion disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2493382A (en) * 1948-10-29 1950-01-03 American Cyanamid Co Automatic sample collector
GB2095818B (en) 1981-03-27 1985-10-02 Exxon Research Engineering Co Staged adsorption/resorption heat pump
US5047324A (en) * 1986-12-09 1991-09-10 Miles Inc. Substantially pure enzyme-antibody conjugate preparations
US5554748A (en) * 1989-04-07 1996-09-10 Nycomed Salutar, Inc. Adducts of macrocyclic chelants
CA2087163A1 (en) * 1990-07-20 1992-01-21 Hubert Agback Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures
US6120768A (en) * 1993-05-17 2000-09-19 Immunomedics, Inc. Dota-biotin derivatives
US5804371A (en) 1994-07-25 1998-09-08 Boehringer Mannheim Gmbh Hapten-labelled peptides
DE59507438D1 (de) * 1994-07-25 2000-01-20 Roche Diagnostics Gmbh Hydrophile metallkomplexe
ES2148540T3 (es) * 1994-07-25 2000-10-16 Roche Diagnostics Gmbh Complejos metalicos con enlazador cargado.
WO1996003652A1 (de) 1994-07-25 1996-02-08 Boehringer Mannheim Gmbh Bestimmung von spezifischem immunglobulin unter verwendung multipler antigene
WO1996003651A1 (de) 1994-07-25 1996-02-08 Boehringer Mannheim Gmbh Metallchelat-markierte peptide
DE4430972A1 (de) * 1994-07-25 1996-02-01 Boehringer Mannheim Gmbh Bestimmung von spezifischem Immunglobulin unter Verwendung multipler Antigene
GB9415143D0 (en) 1994-07-27 1994-09-14 Edwards Raymond Glycated haemoglobin assay
AU3649697A (en) * 1996-06-27 1998-01-14 G.D. Searle & Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications

Also Published As

Publication number Publication date
WO2002027317A3 (en) 2003-09-12
CA2420768A1 (en) 2002-04-04
EP1625857A3 (en) 2008-08-27
CA2420768C (en) 2012-09-25
ES2254489T3 (es) 2006-06-16
WO2002027317A2 (en) 2002-04-04
JP3836429B2 (ja) 2006-10-25
US20040087501A1 (en) 2004-05-06
US7897404B2 (en) 2011-03-01
DE60116146D1 (de) 2006-01-26
EP1625857A2 (en) 2006-02-15
JP2004510162A (ja) 2004-04-02
EP1364208A2 (en) 2003-11-26
AU2001289923A1 (en) 2002-04-08
EP1364208B1 (en) 2005-12-21
ATE313796T1 (de) 2006-01-15

Similar Documents

Publication Publication Date Title
DE3587687T2 (de) Monoklonale Antikörper für HbA1c.
DE69213240T2 (de) Wasserlösliche reagenzien und konjugate auf polymerbasis, die vom divinylsulfon abgeleitete reste enthalten
DE60113445T2 (de) Substanzen mit verzweigten linkermolekülen
DE69333641T2 (de) Methode zur messung der knochenresorption
DE10303974A1 (de) Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP0650053B1 (de) Synthetischer Standard für Immunoassays
EP0491362B1 (de) Verwendung von Peptidpaaren mit extrem hoher spezifischer Affinität zueinander im Bereich der in vitro Diagnostik
DE3850931T2 (de) Heterobifunktionelle Kupplungsmittel.
DE69119656T2 (de) Satz zur spezifischen Bestimmung von Angiotensin-II
DE69224231T2 (de) Verfahren und Zusammensetzungen für Enzymkomplimentationassays unter Verwendung der Omega-Region der Beta-Galactosidase
EP0711415A1 (de) Immunoassay zum nachweis von kollagen oder kollagenfragmenten
DE69132122T2 (de) Reinigung von cytokeratinfragmenten
EP0780687A2 (de) Verfahren zur Herstellung eines synthetischen Kalibrators für Sandwich-Immunoassays
DE10111224B4 (de) Analoge der Ecstasy-Klasse sowie Verwendung derselben beim Nachweis von Verbindungen der Ecstasy-Klasse
DE69422692T2 (de) Verfahren zum Trennen und Messen von Glykoprotein
EP0600326A2 (de) Streptolysin O Peptidantigene und Verfahren zur Bestimmung von Streptolysin-Antikörper
DE4430972A1 (de) Bestimmung von spezifischem Immunglobulin unter Verwendung multipler Antigene
DE69632357T2 (de) Polypeptid und Verfahren zum Messen von Lebendkörperkomponenten unter Verwendung derselben
DE69315989T2 (de) Aminoterminale prokollagen 1(i) peptide
DE69026328T2 (de) Verfahren zum Screenen von Arzneimitteln
DE69028784T2 (de) Testverfahren von glykosylierten proteinen unter verwendung eines antikörpers gerichtet gegen reduzierte glykosylierte n-terminal-aminosäuren
DE3781745T2 (de) Antikoerper zur verwendung fuer die bestimmung von menschlichem glycoalbumin.
DE69028104T2 (de) Verfahren zur proteinbindung-enzym-komplementationstests
DE3851221T2 (de) Nichttrennender festphasen-enzymtest.
JP3836429B2 (ja) 規定した化学量論の結合体

Legal Events

Date Code Title Description
8364 No opposition during term of opposition